Retigabine: the newer potential antiepileptic drug.

Journal Title: Pharmacological Reports - Year 2010, Vol 62, Issue 2

Abstract

Retigabine represents an antiepileptic drug possessing a completely different mechanism of action when compared to the existing classical and newer antiepileptic drugs. In the therapeutic range, retigabine enhances potassium currents, very likely via destabilization of a closed conformation or stabilization of the open conformation of the potassium Kv7.2-7.3 channels. There are also data indicating that this drug may be a GABA enhancer. Kainate-induced status epilepticus in rats resulted in massive apoptosis in the pyriform cortex and hippocampal area - retigabine inhibited neurodegeneration only in the former brain structure. The metabolism of retigabine has nothing to do with cytochrome P450 enzymes and the drug undergoes glucuronidation and acetylation. Randomized, placebo-controlled multicenter studies have shown that retigabine produced a considerable improvement as an add-on drug in patients with partial drug-resistant epilepsy. The most prominent adverse effects due to retigabine combined with the existing antiepileptic treatment were dizziness, somnolence and fatigue. The preclinical data indicate that this antiepileptic drug may possibly be applied in patients with neuropathic pain and affective disorders. Initial clinical data suggest that retigabine may be also effective in Alzheimer's disease or stroke.

Authors and Affiliations

Piotr Czuczwar, Agnieszka Wojtak, Anna Cioczek-Czuczwar, Jolanta Parada-Turska, Ryszard Maciejewski, Stanisław Czuczwar

Keywords

Related Articles

Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression.

The paper describes the effect of amantadine addition to imipramine therapy in patients suffering from treatment-resistant unipolar depression who fulfilled DSM IV criteria for major (unipolar) depression. Fifty patients...

Effects of selective sigma receptor ligands on glucocorticoid receptor-mediated gene transcription in LMCAT cells.

It has been shown previously that sigma receptor agonists reveal potential antidepressant activity in experimental models. Moreover, some data indicate sigma receptor contribution to stress-induced responses (e.g., condi...

Can vitamins C and E restore the androgen level and hypersensitivity of the vas deferens in hyperglycemic rats?

Diabetic neuropathy can affect the male reproductive system. The aim of this study was therefore to evaluate whether antioxidant (vitamins C and/or E) treatment could attenuate reproductive dysfunctions in hyperglycemic...

Physiology and pharmacology of melatonin in relation to biological rhythms.

Melatonin is an evolutionarily conserved molecule that serves a time-keeping function in various species. In vertebrates, melatonin is produced predominantly by the pineal gland with a marked circadian rhythm that is gov...

Anticonvulsant and acute neurotoxic characteristics of nicotinic acid benzylamide:a preclinical study.

The aim of this study was to evaluate time-course and dose-response relationships of nicotinic acid benzylamide (Nic-BZA) with regard to its anticonvulsant activity in the maximal electroshock(MES)-induced seizures and a...

Download PDF file
  • EP ID EP129213
  • DOI -
  • Views 90
  • Downloads 0

How To Cite

Piotr Czuczwar, Agnieszka Wojtak, Anna Cioczek-Czuczwar, Jolanta Parada-Turska, Ryszard Maciejewski, Stanisław Czuczwar (2010). Retigabine: the newer potential antiepileptic drug.. Pharmacological Reports, 62(2), 211-219. https://europub.co.uk./articles/-A-129213